A number of studies have shown that early diagnosis and treatment at a higher CD4+ cell count without ADE could benefit patients in terms of preserving immune function and reducing the risk of mortality [20, 41, 42]. The gene discussed is CD4; the disease is acute disseminated encephalomyelitis.